Kristin A Guertin1, Erikka Loftfield1, Simina M Boca1, Joshua N Sampson1, Steven C Moore1, Qian Xiao1, Wen-Yi Huang1, Xiaoqin Xiong1, Neal D Freedman1, Amanda J Cross1, Rashmi Sinha1. 1. From the Nutritional Epidemiology Branch (KAG, EL, SCM, QX, NDF, and RS), the Biostatistics Branch (JNS), and the Occupational and Environmental Epidemiology Branch (W-YH), Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, MD; the Innovation Center for Biomedical Informatics and Department of Oncology, Georgetown University Medical Center, Washington, DC (SMB); Information Management Services Inc., Silver Spring, MD (XX); and the Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, St. Mary's Campus, Norfolk Place, London, United Kingdom (AJC).
Abstract
BACKGROUND: Coffee intake may be inversely associated with colorectal cancer; however, previous studies have been inconsistent. Serum coffee metabolites are integrated exposure measures that may clarify associations with cancer and elucidate underlying mechanisms. OBJECTIVES: Our aims were 2-fold as follows: 1) to identify serum metabolites associated with coffee intake and 2) to examine these metabolites in relation to colorectal cancer. DESIGN: In a nested case-control study of 251 colorectal cancer cases and 247 matched control subjects from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we conducted untargeted metabolomics analyses of baseline serum by using ultrahigh-performance liquid-phase chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry. Usual coffee intake was self-reported in a food-frequency questionnaire. We used partial Pearson correlations and linear regression to identify serum metabolites associated with coffee intake and conditional logistic regression to evaluate associations between coffee metabolites and colorectal cancer. RESULTS: After Bonferroni correction for multiple comparisons (P = 0.05 ÷ 657 metabolites), 29 serum metabolites were positively correlated with coffee intake (partial correlation coefficients: 0.18-0.61; P < 7.61 × 10(-5)); serum metabolites most highly correlated with coffee intake (partial correlation coefficients >0.40) included trigonelline (N'-methylnicotinate), quinate, and 7 unknown metabolites. Of 29 serum metabolites, 8 metabolites were directly related to caffeine metabolism, and 3 of these metabolites, theophylline (OR for 90th compared with 10th percentiles: 0.44; 95% CI: 0.25, 0.79; P-linear trend = 0.006), caffeine (OR for 90th compared with 10th percentiles: 0.56; 95% CI: 0.35, 0.89; P-linear trend = 0.015), and paraxanthine (OR for 90th compared with 10th percentiles: 0.58; 95% CI: 0.36, 0.94; P-linear trend = 0.027), were inversely associated with colorectal cancer. CONCLUSIONS: Serum metabolites can distinguish coffee drinkers from nondrinkers; some caffeine-related metabolites were inversely associated with colorectal cancer and should be studied further to clarify the role of coffee in the cause of colorectal cancer. The Prostate, Lung, Colorectal, and Ovarian trial was registered at clinicaltrials.gov as NCT00002540.
BACKGROUND: Coffee intake may be inversely associated with colorectal cancer; however, previous studies have been inconsistent. Serum coffee metabolites are integrated exposure measures that may clarify associations with cancer and elucidate underlying mechanisms. OBJECTIVES: Our aims were 2-fold as follows: 1) to identify serum metabolites associated with coffee intake and 2) to examine these metabolites in relation to colorectal cancer. DESIGN: In a nested case-control study of 251 colorectal cancer cases and 247 matched control subjects from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we conducted untargeted metabolomics analyses of baseline serum by using ultrahigh-performance liquid-phase chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry. Usual coffee intake was self-reported in a food-frequency questionnaire. We used partial Pearson correlations and linear regression to identify serum metabolites associated with coffee intake and conditional logistic regression to evaluate associations between coffee metabolites and colorectal cancer. RESULTS: After Bonferroni correction for multiple comparisons (P = 0.05 ÷ 657 metabolites), 29 serum metabolites were positively correlated with coffee intake (partial correlation coefficients: 0.18-0.61; P < 7.61 × 10(-5)); serum metabolites most highly correlated with coffee intake (partial correlation coefficients >0.40) included trigonelline (N'-methylnicotinate), quinate, and 7 unknown metabolites. Of 29 serum metabolites, 8 metabolites were directly related to caffeine metabolism, and 3 of these metabolites, theophylline (OR for 90th compared with 10th percentiles: 0.44; 95% CI: 0.25, 0.79; P-linear trend = 0.006), caffeine (OR for 90th compared with 10th percentiles: 0.56; 95% CI: 0.35, 0.89; P-linear trend = 0.015), and paraxanthine (OR for 90th compared with 10th percentiles: 0.58; 95% CI: 0.36, 0.94; P-linear trend = 0.027), were inversely associated with colorectal cancer. CONCLUSIONS: Serum metabolites can distinguish coffee drinkers from nondrinkers; some caffeine-related metabolites were inversely associated with colorectal cancer and should be studied further to clarify the role of coffee in the cause of colorectal cancer. The Prostate, Lung, Colorectal, and Ovarian trial was registered at clinicaltrials.gov as NCT00002540.
Authors: Leah M Ferrucci; Brenda Cartmel; Annette M Molinaro; David J Leffell; Allen E Bale; Susan T Mayne Journal: Eur J Cancer Prev Date: 2014-07 Impact factor: 2.497
Authors: A F Subar; F E Thompson; V Kipnis; D Midthune; P Hurwitz; S McNutt; A McIntosh; S Rosenfeld Journal: Am J Epidemiol Date: 2001-12-15 Impact factor: 4.897
Authors: P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: R B Hayes; D Reding; W Kopp; A F Subar; N Bhat; N Rothman; N Caporaso; R G Ziegler; C C Johnson; J L Weissfeld; R N Hoover; P Hartge; C Palace; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Mary C Playdon; Regina G Ziegler; Joshua N Sampson; Rachael Stolzenberg-Solomon; Henry J Thompson; Melinda L Irwin; Susan T Mayne; Robert N Hoover; Steven C Moore Journal: Am J Clin Nutr Date: 2017-06-28 Impact factor: 7.045
Authors: Giuseppe Grosso; Agnieszka Micek; Justyna Godos; Salvatore Sciacca; Andrzej Pajak; Miguel A Martínez-González; Edward L Giovannucci; Fabio Galvano Journal: Eur J Epidemiol Date: 2016-10-03 Impact factor: 8.082
Authors: Eline H van Roekel; Erikka Loftfield; Rachel S Kelly; Oana A Zeleznik; Krista A Zanetti Journal: Metabolomics Date: 2019-01-07 Impact factor: 4.290
Authors: Mary C Playdon; Joshua N Sampson; Amanda J Cross; Rashmi Sinha; Kristin A Guertin; Kristin A Moy; Nathaniel Rothman; Melinda L Irwin; Susan T Mayne; Rachael Stolzenberg-Solomon; Steven C Moore Journal: Am J Clin Nutr Date: 2016-08-10 Impact factor: 7.045
Authors: Kaitlyn M Mazzilli; Kathleen M McClain; Loren Lipworth; Mary C Playdon; Joshua N Sampson; Clary B Clish; Robert E Gerszten; Neal D Freedman; Steven C Moore Journal: J Nutr Date: 2020-04-01 Impact factor: 4.798
Authors: Jie Shen; Yuanqing Ye; David W Chang; Maosheng Huang; John V Heymach; Jack A Roth; Xifeng Wu; Hua Zhao Journal: Lung Cancer Date: 2017-11-02 Impact factor: 5.705